NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report

• <1% of cervical cancers are sarcomas. • Data on neurofibrosarcoma management is scarce. • Larotrectinib is approved for NTRK1 gene fusion tumors without acquired resistance. • Targeted therapy of tumor genes may expand treatment for a rare cervical sarcoma.

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol Rep
Main Authors: Wells, A.E., Mallen, A.M., Bui, M.M., Reed, D.R., Apte, S.M.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2019
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6506462/
https://ncbi.nlm.nih.gov/pubmed/31080864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2019.04.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados